A Novel Desensitization Protocol for Infliximab Hypersensitivity in a 13- Year Old Patient with Pustular Psoriasis

(E-pub Ahead of Print)

Author(s): Sapan Kumar Behera, Sandhiya Selvarajan*, Jerene Mathews, Chandana Shajil, Saibal Das, Malathi Munisamy, Alphienes Stanley Xavier.

Journal Name: Current Drug Safety

Become EABM
Become Reviewer


Background: Drug hypersensitivity reactions to infliximab have been reported in pediatric patients. At times, these patients may need infliximab administration in spite of hypersensitivity. However, only a few reports of desensitization protocols are available in the literature in pediatric patients.

Case report: We report a case of immediate hypersensitivity reaction to intravenous infliximab in a 13-year-old child suffering from pustular psoriasis who eventually underwent a 14 step desensitization protocol for the administration of infliximab in a pediatric intensive care unit.

Conclusion: Although our desensitization protocol was safe and effective, we recommend the entire desensitization procedure to be performed under supervision of experienced personnel in a pediatric intensive care unit. Future studies with larger sample size are needed to confirm our findings.

Keywords: Desensitization, infliximab, monoclonal antibody, pediatric, psoriasis

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1574886314666190119115632
Price: $95

Article Metrics

PDF: 3